Breaking News, Collaborations & Alliances

OctoPlus Signs CR Deal

Drug delivery pact with unnamed U.S. partner

OctoPlus N.V. has signed a feasibility agreement with a U.S.-based pharmaceutical company relating to the use of OctoPlus’ controlled release technology. OctoPlus will develop a controlled release formulation of an undisclosed compound using its proprietary drug delivery technology PolyActive®.

If the evaluation is successful, the companies may decide to enter into a full process development, manufacturing and licensing agreement. Financial terms of the current agreement are not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters